
ASSEMBLY BIOSCIENCES, INC.
100
Recent updates include Assembly Biosciences reporting third quarter 2026 financial results with a net loss and ongoing clinical progress across its pipeline. The company elected to share development costs and profits with Gilead for the HPI program in the U.S. Phase 2 studies for the HDV entry inhibitor ABI-6250 have been initiated, and regulatory enabling studies continue for other candidates.
- Assembly Biosciences reported a net loss of $20.3 million and basic and diluted EPS of -$0.93 for Q3 2026, with strong liquidity including a current ratio of 12.89 as of September 30, 2026 [N1][N2][S2].
- Following review of Gilead’s clinical development plan for the HPI program, Assembly elected to cover 40% of U.S. development costs and share 40% of operating profits and losses in the U.S. [S2].
- Phase 2 dosing was initiated in October 2026 for ABI-6250 targeting HDV, alongside a Phase 1 hepatic impairment study [S2][N1].
- A Study May Proceed letter was received from the FDA for a planned Phase 2 study of ABI-6250 in primary biliary cholangitis and primary sclerosing cholangitis, with study preparation underway [S2].
- ABI-7272 completed GLP toxicology studies and is undergoing regulatory filing-enabling studies [S2].
- The company continues a partnering process for ABI-4334 and does not plan to advance it further without a partner [S2].
- A new development candidate, ABI-8914, targeting respiratory viruses, was nominated and is advancing into regulatory filing-enabling studies [S2].
Assembly Biosciences is a clinical-stage biotechnology company developing small-molecule therapeutics targeting viral and liver diseases with significant unmet medical needs. Its pipeline includes investigational therapies for recurrent genital herpes (two long-acting helicase-primase inhibitors, 1179 and 5366), hepatitis delta virus (oral NTCP inhibitor ABI-6250), hepatitis B virus (capsid assembly modulator ABI-4334), and transplant-related herpesviruses (non-nucleoside polymerase inhibitor ABI-7272). The company collaborates with Gilead Sciences, which licensed the HPI program and shares development costs and profits in the U.S. Assembly’s clinical programs have demonstrated potent antiviral activity and favorable safety profiles in Phase 1 studies, supporting advancement to Phase 2. The company also pursues partnering for its HBV program and continues research on novel viral targets. Financially, Assembly reported a net loss for Q3 2026 and maintains strong liquidity ratios as of September 30, 2026.
Assembly Biosciences, Inc. is a biotechnology company focused on developing innovative small-molecule therapeutics targeting serious viral and liver diseases, including recurrent genital herpes, hepatitis delta virus (HDV), hepatitis B virus (HBV), and cholestatic liver diseases. The company’s pipeline includes multiple clinical-stage candidates such as two long-acting helicase-primase inhibitors (HPIs) licensed to Gilead Sciences, an orally bioavailable NTCP inhibitor for HDV and cholestatic liver diseases, a next-generation capsid assembly modulator for HBV, and a broad-spectrum non-nucleoside polymerase inhibitor for transplant-related herpesviruses. Assembly reported a net loss of $20.3 million and basic and diluted EPS of -$0.93 for the quarter ended September 30, 2026. The company maintains strong liquidity with a current ratio of 12.89 and cash ratio of 6.77 as of the same date. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Assembly Biosciences has advanced multiple clinical-stage candidates with novel mechanisms targeting significant viral diseases. Positive Phase 1 data for its helicase-primase inhibitors demonstrated potent antiviral activity and favorable safety, supporting progression to Phase 2 studies. The collaboration with Gilead Sciences for the HPI program provides a strong partner for late-stage development and commercialization. The initiation of Phase 2 studies for its HDV entry inhibitor and ongoing regulatory enabling studies for other candidates indicate active pipeline advancement. Strong liquidity supports continued development activities. These elements collectively indicate a robust clinical and strategic foundation.
Assembly Biosciences operates in a high-risk biotechnology environment with clinical-stage assets that have yet to achieve regulatory approval or commercial success. The company reported a net loss and negative earnings per share for the recent quarter, reflecting ongoing development costs without current product revenues. Its HBV capsid assembly modulator program is dependent on securing a partner to advance development. The HPI program is now controlled by Gilead Sciences, limiting Assembly’s direct control over these assets. Clinical and regulatory risks inherent in drug development, potential competition, and market adoption challenges remain significant. The company’s financial sustainability depends on continued capital availability and successful clinical outcomes.
Assembly Biosciences’ moat derives from its specialized focus on innovative small-molecule antivirals targeting serious viral and liver diseases with high unmet medical needs. Its proprietary helicase-primase inhibitors for recurrent genital herpes represent a novel mechanism of action distinct from existing nucleoside analog therapies, addressing resistance and dosing limitations. The collaboration with Gilead Sciences provides access to late-stage development and commercialization expertise, enhancing the potential reach of its therapies. The company’s pipeline includes multiple clinical-stage candidates with demonstrated antiviral activity and favorable safety profiles, supported by a strong research and development team with a track record of approved drugs. These factors contribute to a differentiated position in the antiviral therapeutics space.
• Clinical Development Risk: Assembly’s investigational therapies are in early to mid-stage clinical development and may not demonstrate safety or efficacy sufficient for regulatory approval.
• Dependence on Collaboration: The company’s HPI program is licensed to Gilead Sciences, limiting Assembly’s control over development and commercialization decisions for these assets.
• Financial Risk: Assembly reported net losses and negative earnings per share, reflecting ongoing expenses without product revenues, which may require additional financing.
• Partnering Risk: Advancement of the HBV capsid assembly modulator program depends on securing a development partner; failure to do so may delay or halt progress.
• Regulatory and Market Risk: Approval and market acceptance of novel antiviral therapies face regulatory scrutiny and competitive challenges, which may impact commercial success.
Business trends: Advancement of novel antiviral therapies targeting recurrent genital herpes, HDV, HBV, and liver diseases with clinical data supporting progression and collaboration with Gilead.
Execution milestones: Initiation and progress of Phase 2 studies for key candidates, completion of toxicology and regulatory enabling studies, and active partnering efforts.
Key risks: Clinical development uncertainties, reliance on collaboration and partners for advancement, financial sustainability amid ongoing losses, and regulatory and market acceptance challenges.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Assembly Biosciences is a biotechnology company developing small-molecule therapeutics targeting serious viral and liver diseases, including recurrent genital herpes, hepatitis delta virus (HDV), hepatitis B virus (HBV), and cholestatic liver diseases (CLDs).
- The company’s pipeline includes clinical-stage investigational therapies: two long-acting helicase-primase inhibitors (HPIs) GS-1179 and GS-5366 for recurrent genital herpes, an orally bioavailable NTCP inhibitor ABI-6250 for HDV and CLDs, a next-generation capsid assembly modulator ABI-4334 for HBV, and a broad-spectrum non-nucleoside polymerase inhibitor ABI-7272 for transplant-related herpesviruses.
- Assembly has a collaboration with Gilead Sciences, which exercised its option to license the HPI program including 1179 and 5366 in December 2025. Assembly elected to cover 40% of U.S. development costs and share 40% of operating profits and losses for the HPI program in the U.S.
- Clinical data for 5366 showed potent antiviral activity with significant reductions in HSV-2 shedding and genital lesion rates, supporting once-weekly and potentially once-monthly oral dosing. 5366 was well-tolerated with mostly mild adverse events.
- Clinical data for 1179 showed highly potent antiviral activity with a 97% reduction in HSV-2 shedding rate and 92% reduction in lesion rate at 50 mg weekly dose, with a favorable safety profile and support for once-weekly dosing.
- The company initiated Phase 2 studies for ABI-6250 in HDV and plans Phase 2 studies in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) for CLDs, with Phase 1 hepatic impairment study also initiated.
- ABI-7272 completed GLP toxicology studies and is undergoing regulatory filing-enabling studies.
- ABI-4334 is in a partnering process; Assembly does not plan to advance it further without a partner.
- Assembly nominated ABI-8914 targeting respiratory viruses, advancing into regulatory filing-enabling studies.
- Financial snapshot as of 2026-09-30 shows cash and equivalents of $29.1 million, current assets of $321.2 million, current liabilities of $24.9 million, resulting in a current ratio of 12.89 and cash ratio of 6.77, indicating strong liquidity.
- Net loss for the quarter ended 2026-09-30 was $20.3 million with basic and diluted EPS of -$0.93.
- The company’s strategy focuses on advancing next-generation therapeutics addressing high unmet medical needs with significant market opportunities, leveraging deep virology expertise and collaborations.
- The company reported third quarter 2026 financial results and recent updates in November 2026, including progress on clinical programs and collaboration terms with Gilead.
- Assembly’s HPI program development is now under Gilead’s control following option exercise; Assembly participates in profit-sharing in the U.S.
- The company’s clinical programs have presented data at major scientific congresses including ESCMID and AASLD.
- Assembly’s pipeline targets diseases with significant global prevalence and unmet medical needs, such as HBV affecting 240 million people worldwide and HDV affecting approximately 12 million.
- The company’s HPI candidates 1179 and 5366 have demonstrated antiviral activity against HSV-1 and HSV-2, including strains resistant to nucleoside analogs.
- Assembly’s ABI-6250 targets NTCP to inhibit HBV and HDV entry into hepatocytes, aiming to provide an oral alternative to injectable therapies.
- The company’s clinical data show favorable safety profiles across its investigational therapies with mostly mild to moderate adverse events and no serious adverse events reported to date.
Generated 2026-11-15
- S1 | 2026-03-19 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | Assembly Biosciences, Inc. Reports Third Quarter 2026 Financial Results and Recent Updates | https://www.nasdaq.com/articles/assembly-biosciences-inc-reports-third-quarter-2026-financial-results-and-recent-updates
- N2 | 2026-11-12 | www.nasdaq.com | Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/assembly-biosciences-asmb-reports-q3-loss-lags-revenue-estimates
- N3 | 2026-11-12 | www.nasdaq.com | Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/sol-gel-technologies-ltd-slgl-reports-q3-loss-misses-revenue-estimates
- N4 | 2026-11-05 | www.nasdaq.com | Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/amphastar-pharmaceuticals-amph-tops-q3-earnings-and-revenue-estimates
- N5 | 2026-09-08 | www.nasdaq.com | Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services | https://www.nasdaq.com/articles/zackscom-featured-highlights-include-eurodry-rcm-assembly-biosciences-delcath-and-national
- N6 | 2026-03-19 | www.nasdaq.com | Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates | https://www.nasdaq.com/articles/assembly-biosciences-asmb-q4-earnings-and-revenues-top-estimates
- N7 | 2026-03-05 | www.nasdaq.com | Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/metagenomi-therapeutics-mgx-reports-q4-loss-misses-revenue-estimates
- N8 | 2026-02-26 | www.nasdaq.com | Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/personalis-psnl-reports-q4-loss-misses-revenue-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


